A REVIEW OF TESTOSTERONE

At the conclusion of their cycle, hematocrit stages experienced greater by 3%-place compared with baseline. The increase was not linked to lengthier use or greater AAS dose. A reason behind this is likely to be that, further than a particular standard of androgenic action, no additional raise of hematocrit happens: a ‘ceiling outcome’. Notably,